LRP2BP

Across TCGA pan-cancer cohorts, LRP2BP mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LRP2BP data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LRP2BP mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LRP2BP expression acts as an unfavorable survival marker.

PDAC and GBM are the cancer types where LRP2BP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.531	0.923	.022	3	view →
GBM	OS	Quartile	All	0.328	0.626	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

LRP2BP–PDAC (DFS)

Open the PDAC breakdown →